Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis.

RATIONALE AND OBJECTIVES The authors intended to confirm previous findings that paramagnetic porphyrins are avid only for intratumoral nonviable tissues, but not for viable tumor cells, and to test the hypothesis that necrosis, regardless of location and origin, can be visualized by metalloporphyrin enhanced magnetic resonance imaging (MRI). METHODS Intravenous administrations of gadolinium mesoporphyrin (Gd-MP), manganese tetraphenylporphyrin (Mn-TPP), manganese methylpyrroporphyrin-gadopentetate dimeglumine complex (Mn-MPP-Gd) and manganese tetra(4-sulfonatophenyl)porphyrin (MnTPPS4) at 0.05 mmol/kg were compared with those of gadopentetate dimeglumine (Gd-DTPA) at 0.1 mmol/kg in 38 rats with cholestatic liver necrosis, alcohol- and laser-induced coagulation necrosis in liver, and skeletal muscle, reperfused hepatic infarction, and segmental renal infarction. T1-weighted spin echo MRI (TR/TE = 300/15 mseconds) was acquired before and as long as 48 hours after injection, matched with histologic findings, and correlated with Gd/ Mn tissue content measurements. RESULTS Both Gd-DTPA and the four metalloporphyrins initially caused a similar nonspecific negative contrast enhancement in the necrosis. However, a strong and persisting positive enhancement (necrosis-to-normal contrast ratio ranging from 1.5 to 2.0) developed only with metalloporphyrins in all types of necrosis. In liver and kidney, Gd and Mn concentrations at 24 hours were comparable in necrotic and normal tissues. In muscle, the concentrations were more than eight times higher in necrotic than in normal tissue. CONCLUSIONS The implied affinity of metalloporphyrins for necrosis with presumably increased relaxivity suggests a possible mode of targetability for MRI contrast media that may elicit novel applications.

[1]  P D Schneider,et al.  Liver resection and laser hyperthermia. , 1992, The Surgical clinics of North America.

[2]  R. Lauffer,et al.  Targeted relaxation enhancement agents for MRI , 1991, Magnetic resonance in medicine.

[3]  D Revel,et al.  Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging. A study of human carcinoma, lymphoma, and fibrosarcoma in mice. , 1987, Investigative radiology.

[4]  J. Sessler,et al.  Preclinical Evaluation of Gadolinium (III) Texaphyrin Complex: A New Paramagnetic Contrast Agent for Magnetic Resonance Imaging , 1994, Investigative radiology.

[5]  R. Fiel,et al.  A comparative study of manganese meso-sulfonatophenyl porphyrins: contrast-enhancing agents for tumors. , 1990, Magnetic resonance imaging.

[6]  S. H. Koenig,et al.  Tissue distribution and stability of metalloporphyrin MRI contrast agents , 1987, Magnetic resonance in medicine.

[7]  D I Rosenthal,et al.  Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size. , 1996, Academic radiology.

[8]  C. Compton,et al.  Radio-frequency tissue ablation of VX2 tumor nodules in the rabbit lung. , 1996, Academic radiology.

[9]  U Schmiedl,et al.  Porphyrins as contrast media , 1991, Magnetic resonance in medicine.

[10]  U Schmiedl,et al.  Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. , 1990, Investigative radiology.

[11]  A. Sharma,et al.  MnPcS4: a new MRI contrast enhancing agent for tumor localisation in mice. , 1995, Magnetic resonance imaging.

[12]  J. Winkelman,et al.  The concentration in tumor and other tissues of parenterally administered tritium- and 14-C-labeled tetraphenylporphinesulfonate. , 1967, Cancer research.

[13]  J. S. Cohen,et al.  Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging , 1984, FEBS letters.

[14]  K. Hossmann,et al.  Proton relaxation enhancement in experimental brain tumors--in vivo NMR study of manganese(III)TPPS in rat brain gliomas. , 1990, Magnetic resonance imaging.

[15]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[16]  P. Furmanski,et al.  Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. , 1988, Cancer research.

[17]  S. Bown,et al.  Role of interstitial therapy in the treatment of liver cancer , 1991, The British journal of surgery.

[18]  Thierry Patrice,et al.  Tetra‐p‐aminophenylporphyrin conjugated with Gd‐DTPA: Tumor‐specific contrast agent for MR imaging , 1993, Journal of magnetic resonance imaging : JMRI.

[19]  C J Gomer,et al.  Photodynamic therapy in the treatment of malignancies. , 1989, Seminars in hematology.

[20]  P. V. van Zijl,et al.  MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. , 1992, Magnetic resonance imaging.

[21]  A L Baert,et al.  Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings. , 1995, Academic radiology.

[22]  G. Glover,et al.  Experimental Hepatic Tumor Necrosis: Comparison of Spin-Echo and Pulsed Magnetization Transfer Contrast Magnetic Resonance Imaging , 1993, Investigative radiology.

[23]  D. Kessel,et al.  Porphyrin localization: a new modality for detection and therapy of tumors. , 1984, Biochemical pharmacology.